regardless of promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from PBMs. These organizations are typically building limitations to coverage, like significant expense requirements and prior authorization that hinder consumer availability. Indus